关注
Rachel G. Liao
Rachel G. Liao
Broad Institute of MIT and Harvard
在 broadinstitute.org 的电子邮件经过验证
标题
引用次数
引用次数
年份
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7412021
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
H Greulich, B Kaplan, P Mertins, TH Chen, KE Tanaka, CH Yun, X Zhang, ...
Proceedings of the National Academy of Sciences 109 (36), 14476-14481, 2012
3252012
Whole-genome sequencing reveals host factors underlying critical COVID-19
A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ...
Nature 607 (7917), 97-103, 2022
2362022
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma
RG Liao, J Jung, J Tchaicha, MD Wilkerson, A Sivachenko, ...
Cancer research 73 (16), 5195-5205, 2013
2032013
BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
MS Cline, RG Liao, MT Parsons, B Paten, F Alquaddoomi, A Antoniou, ...
PLoS genetics 14 (12), e1007752, 2018
2002018
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
L Tan, J Wang, J Tanizaki, Z Huang, AR Aref, M Rusan, SJ Zhu, Y Zhang, ...
Proceedings of the National Academy of Sciences 111 (45), E4869-E4877, 2014
1942014
Facilitating a culture of responsible and effective sharing of cancer genome data
LL Siu, M Lawler, D Haussler, BM Knoppers, J Lewin, DJ Vis, RG Liao, ...
Nature medicine 22 (5), 464-471, 2016
1002016
Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells
J Wang, O Mikse, RG Liao, Y Li, L Tan, PA Janne, NS Gray, KK Wong, ...
Oncogene 34 (17), 2167-2177, 2015
842015
A Loss-of-Function Splice Acceptor Variant in IGF2 Is Protective for Type 2 Diabetes
JM Mercader, RG Liao, AD Bell, Z Dymek, K Estrada, T Tukiainen, ...
Diabetes 66 (11), 2903-2914, 2017
622017
Targeted therapy for squamous cell lung cancer
RG Liao, H Watanabe, M Meyerson, PS Hammerman
Lung cancer management 1 (4), 293-300, 2012
572012
RAS–MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade
B Bockorny, M Rusan, W Chen, RG Liao, Y Li, F Piccioni, J Wang, L Tan, ...
Molecular cancer therapeutics 17 (7), 1526-1539, 2018
552018
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC
JH Tchaicha, EA Akbay, A Altabef, OR Mikse, E Kikuchi, K Rhee, RG Liao, ...
Cancer research 74 (17), 4676-4684, 2014
432014
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues
M D’Antonio, JP Nguyen, TD Arthur, H Matsui, BM Neale, M Daly, ...
Cell reports 37 (7), 2021
292021
Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape
DJ Vis, J Lewin, RG Liao, M Mao, F Andre, RL Ward, F Calvo, BT Teh, ...
Annals of Oncology 28 (5), 1145-1151, 2017
202017
BRCA1/2 variant data-sharing practices
JM Bollinger, A Sanka, L Dolman, RG Liao, R Cook-Deegan
The Journal of Law, Medicine & Ethics 47 (1), 88-96, 2019
112019
Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.
JH Lewin, DJ Vis, EE Voest, R Liao, PM Nederlof, BA Conley, DB Solit, ...
Journal of Clinical Oncology 34 (15_suppl), 11502-11502, 2016
32016
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC
EA Akbay, JH Tchaicha, A Altabef, OR Mikse, E Kikuchi, K Rhee, R Liao, ...
Cancer Research 74 (19_Supplement), 4851-4851, 2014
12014
COVID-19 Host Genetics Initiative. A first update on mapping the human genetic architecture of COVID-19
GA Pathak, R Polimanti, J Karjalainen, M Daly, A Ganna, MJ Daly, ...
University of Leicester, 2022
2022
Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey
J Lewin, DJ Vis, M Lawler, R Liao, M Mao, BT Teh, W Sellers, R Ward, ...
Cancer Research 76 (14_Supplement), 1832-1832, 2016
2016
Heterogeneity of mutation calling and annotation: a survey of cancer next-generation sequencing initiatives by the Global Alliance for Genomics and Health (GA4GH)
DJ Vis, J Lewin, L Siu, R Liao, JC Zenklusen, F Calvo, E Szepessy, ...
Cancer Research 76 (14_Supplement), 5287-5287, 2016
2016
系统目前无法执行此操作,请稍后再试。
文章 1–20